Profile data is unavailable for this security.
About the company
Hepion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of drug therapy for treatment of chronic liver diseases. The Company is developing a treatment for non-alcoholic steatohepatitis (NASH), hepatocellular carcinoma (HCC), and other chronic liver diseases. Its cyclophilin inhibitor, rencofilstat, is being developed to offer benefits to address multiple complex pathologies related to the progression of liver disease. It is developing rencofilstat as its lead molecule. Rencofilstat is a compound that binds and inhibits the function of a specific class of isomerase enzymes called cyclophilins that regulate protein folding, in addition to other activities. It has developed and maintains an artificial intelligence deep machine learning (AI/ML) platform designed to understand disease processes and identify patients that are rencofilstat responders. In addition, its AI/ML can be used to further NASH and HCC clinical development programs.
- Revenue in USD (TTM)0.00
- Net income in USD-48.93m
- Incorporated2013
- Employees22.00
- LocationHepion Pharmaceuticals Inc399 Thornall StEDISON 08837-2236United StatesUSA
- Phone+1 (732) 902-4000
- Fax+1 (732) 902-4100
- Websitehttps://hepionpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tenax Therapeutics Inc | 0.00 | -7.71m | 7.52m | 5.00 | -- | 0.1414 | -- | -- | -33.51 | -33.51 | 0.00 | 27.15 | 0.00 | -- | -- | 0.00 | -102.20 | -199.16 | -159.72 | -285.64 | -- | -- | -- | -- | -- | -82.13 | 0.0583 | -- | -- | -- | 30.21 | -- | -- | -- |
| Trevena Inc | 3.13m | -40.29m | 7.56m | 23.00 | -- | -- | -- | 2.42 | -3.16 | -3.16 | 0.2611 | -0.4429 | 0.07 | 3.69 | -- | 135,869.60 | -90.25 | -55.93 | -110.38 | -66.35 | 46.56 | -- | -1,289.25 | -3,134.41 | 4.66 | -15.43 | 1.33 | -- | 847.61 | -11.43 | 24.93 | -- | -24.67 | -- |
| Plus Therapeutics Inc (USA) | 4.91m | -13.32m | 7.70m | 20.00 | -- | -- | -- | 1.57 | -4.51 | -4.51 | 1.57 | -0.3033 | 0.2787 | -- | -- | 245,650.00 | -75.54 | -59.18 | -210.10 | -133.04 | -- | -- | -271.04 | -470.45 | -- | -- | 1.51 | -- | 2,093.30 | -5.89 | 34.32 | -- | 3.77 | -- |
| Paranovus Entertainment Technology Ltd | 51.46m | -42.62m | 7.78m | 80.00 | -- | 0.7284 | -- | 0.1511 | -7.16 | -7.49 | 9.89 | 1.46 | 1.18 | 59.61 | 4.15 | 643,209.90 | -91.12 | -23.19 | -119.36 | -27.21 | 4.92 | 23.09 | -77.15 | -24.25 | 3.97 | -2,465.22 | 0.00 | -- | 9.68 | 9.80 | -45.84 | -- | -21.93 | -- |
| Cadrenal Therapeutics Inc | 0.00 | -8.36m | 7.85m | 4.00 | -- | 0.8304 | -- | -- | -0.7044 | -0.7044 | 0.00 | 0.5907 | 0.00 | -- | -- | 0.00 | -179.77 | -- | -234.22 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.47 | -- | -- | -- |
| Virios Therapeutics Inc | 0.00 | -5.30m | 7.92m | 4.00 | -- | -- | -- | -- | -0.283 | -0.283 | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 56.76 | -- | -- | -- |
| Hepion Pharmaceuticals Inc | 0.00 | -48.93m | 7.99m | 22.00 | -- | 1.26 | -- | -- | -12.41 | -12.41 | 0.00 | 1.51 | 0.00 | -- | -- | 0.00 | -124.91 | -61.43 | -150.17 | -68.82 | -- | -- | -- | -- | -- | -4,784.14 | 0.00 | -- | -- | -- | -7.92 | -- | -- | -- |
| Cyclerion Therapeutics Inc | 0.00 | -12.59m | 8.01m | 1.00 | -- | 0.6477 | -- | -- | -5.22 | -2.29 | 0.00 | 4.56 | 0.00 | -- | -- | 0.00 | -80.08 | -72.70 | -115.85 | -86.96 | -- | -- | -- | -2,565.62 | -- | -- | 0.00 | -- | -100.00 | -- | 30.98 | -- | -- | -- |
| Sentient Brands Holdings Inc | 160.00 | -379.70k | 8.04m | 2.00 | -- | -- | -- | 50,249.23 | -0.007 | -0.007 | 0.00 | -0.0308 | 0.0006 | -0.0026 | -- | 80.00 | -149.74 | -224.47 | -- | -- | 462.50 | 41.35 | -237,312.50 | -27,393.23 | 0.0005 | -0.6995 | -- | -- | -16.18 | -- | -100.19 | -- | -- | -- |
| Longeveron Inc | 709.00k | -22.21m | 8.40m | 23.00 | -- | 4.12 | -- | 11.84 | -10.18 | -10.18 | 0.3262 | 0.4245 | 0.0359 | -- | 4.31 | 30,826.09 | -108.45 | -63.15 | -139.35 | -75.68 | 31.17 | 33.70 | -3,020.17 | -441.02 | -- | -- | 0.00 | -- | -41.98 | -19.78 | -17.92 | -- | 26.80 | -- |
| NuCana PLC (ADR) | 0.00 | -34.66m | 8.46m | 25.00 | -- | 0.4529 | -- | -- | -412.00 | -412.00 | 0.00 | 8.83 | 0.00 | -- | -- | 0.00 | -64.21 | -41.01 | -102.19 | -48.07 | -- | -- | -- | -- | -- | -77.43 | 0.0259 | -- | -- | -- | 13.71 | -- | -21.70 | -- |
| Notable Labs Ltd | 310.00k | -11.26m | 8.57m | 16.00 | -- | 0.5669 | -- | 27.64 | -3.08 | -3.08 | 0.0939 | 1.68 | 0.0126 | -- | -- | 19,375.00 | -45.79 | -52.02 | -56.70 | -62.09 | 36.45 | 60.19 | -3,633.55 | -3,636.93 | -- | -- | 0.0221 | -- | -52.89 | -11.93 | 65.13 | -- | -50.69 | -- |
| Endexx Corp | 4.64m | 6.93m | 8.61m | -- | 1.28 | -- | 1.45 | 1.86 | 0.0133 | 0.0133 | 0.0091 | -0.0255 | 0.6773 | 4.37 | 13.54 | -- | 86.51 | -- | -- | -- | 28.73 | -- | 127.74 | -- | 0.0664 | -- | -- | -- | 228.66 | -- | 28.26 | -- | -- | -- |
Data as of May 03 2024. Currency figures normalised to Hepion Pharmaceuticals Inc's reporting currency: US Dollar USD
17.14%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Armistice Capital LLCas of 31 Dec 2023 | 418.00k | 9.64% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 159.00k | 3.67% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 82.95k | 1.91% |
| Geode Capital Management LLCas of 31 Dec 2023 | 34.91k | 0.81% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 15.68k | 0.36% |
| Susquehanna Financial Group LLLPas of 31 Dec 2023 | 14.64k | 0.34% |
| Virtu Americas LLCas of 31 Dec 2023 | 12.49k | 0.29% |
| PNC Bank, NA (Investment Management)as of 31 Dec 2023 | 2.88k | 0.07% |
| Tower Research Capital LLCas of 31 Dec 2023 | 1.62k | 0.04% |
| Morgan Stanley & Co. LLCas of 31 Dec 2023 | 1.39k | 0.03% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
